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Abstract:
Curcumin, an active constituent of turmeric, has been shown to possess inhibitory effect of cell 
proliferation and induction of apoptosis towards a board range of tumors. Cell inhibition 
activities of curcumin are behaved differently in various cell types. To investigate the mechanism 
basis for the cell inhibition of curcumin on breast cancer cell lines, we examine curcumin effect 
on NFκB, cell cycle regulatory proteins and matrix metalloproteinases (MMPs) in two breast 
cancer cell lines (MDA-MB-231 and BT-483). Cell proliferation was performed by water soluble 
tetrazolium WST-1 assay. The effect of curcumin’s on the activity of matrix metalloproteinase-1, 
3, 9 were analyzed by RT-PCR. Cell cycle regulatory protein including cyclin D1, CDK4 and 
p21 were examined by immunochemistry. The expressions of NFκB in breast cancer cells treated 
with curcumin were studied by immunochemistry and western blot. The results from WST-1 cell 
proliferation assay showed that curcumin exhibited the anti-proliferation effect on 
MDA-MB-231 and BT-483 cells in a time- and dose-dependent manner. In response to the 
treatment, while, the expression of cyclin D1 had declined in MDA-MB-231 and the expression
of CDK4 in BT-483 had declined. MMP1 mRNA expression in BT-483 and MDA-MB-231 had 
significantly decreased in curcumin treatment group compared with control group. Our finding 
extrapolates the antitumor activity of curcumin in mediating the breast cancer cell proliferative 
rate and invasion by down-regulating the NFκB inducing genes.
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Introduction
The first-line treatment of breast cancer is usually relied on surgery and radiotherapy, and is 
frequently supplemented by adjuvant chemo- or hormonotherapies. Unfortunately, breast cancer 
is highly resistant to chemotherapy, It has an urgent need in developing novel anticancer agents 
presenting low cytotoxic side-effects, but effective inhibit tumor cell proliferation pathway[1, 2].
Curcumin, a phenolic compound extract from rhizome of the plant Curcuma longa is found to 
have inhibitory effects towards a board range of tumors. In breast cancer, curcumin’s anticancer 
effect has been anticipated in relating to induce apoptosis at G2 phase of cell cycle via a 
p53-dependent pathway [3], but it’s role in G1/S transition of breast cancer has not been 
established well. Based on the evolving understanding of molecular basis of breast cancer, it has 
been explained that pathways activated by NFκB up-regulation are implicated not only in cell 
proliferation including cyclin D1 [4] but also regulate promoters that encode several MMPs. 
Therefore, in this study, we attempt to investigate the cell inhibition activity of curcumin on the 
NFκB and its regulatory genes including G1 cyclins and MMPs in BT-438 breast cancer cells 
and MDA-MB-231 breast cancer cells. Estrogen Receptor (ER) positive breast cancers are often
beneficial from anti-hormonal drugs on either inhibiting interaction of oestradiol with ER or 
interrupting oestradiol synthesis. However, ER negative breast cancer, being lack of functional 
estrogen receptor, cannot be targeted by these therapies and are more aggressive with poorer 
prognoses[5]. In our study, we used the MDA-MB-231 and BT-483 human breast cancer cell line 
as the model of ER-negative and ER-positive breast cancers respectively in comparing. 
Materials and Methods
Curcumin(Molecular Weight 368.38) purchased from Sigma Chemicals (St. Louis, MO) was 
accurately weighed and dissolved in dimethyl sulphoxide (DMSO) (Sigma, St. Louis, MO) to a 
concentration of 500μg/mL as a stock solution. It was diluted (50μg/mL) in DMEM and 
Leibovitz's L-15 supplemented with fetal bovine serum (10%) (Invitrogen, Carlsbad, California, 
US) respectively. The dilution (50μg/mL) was further diluted with supplemented medium to a 
series of concentrations.
Both of ER-positive breast cancer cell line BT-483 and ER-negative breast cancer cell line 
MDA-MB-231 were bought from the American Type Culture Collection (Rockville, MD, USA).
BT-483 were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with fetal 
bovine serum (10%), l-glutamine (2 mM) and antibiotics (penicillin100 units/ml; streptomycin 
100 mg/ml) at 37°C in an atmosphere of 5% CO2, while MDA-MB-231 cells were grown in 
Leibovitz's L-15 medium with 2 mM L-glutamine, supplemented with fetal bovine serum (10%), 
l-glutamine (2mM) and antibiotics (penicillin100 units/ml; streptomycin 100 mg/ml) at 37°C 
without CO2. Cells were cultured at a density of 5 × 103 cells/well into 96-well plates. Cell 
growth was followed for 24 and 48 hr after stimulation in the presence or absence of curcumin (1, 
1.25, 2.5, 5, 10, 20 μg/mL, namely 2.7, 4.1, 6.8, 13.6, 27, 54μM,). Medium alone was a negative 
control. Cell proliferation was assessed in vitro using the water soluble tetrazolium WST-1 
(Roche, Indianapolis, IN).
Human breast cancer lines MDA-MB-231 and BT-483 were cultured with curcumin at the 
concentration of 2.5 μg/mL and 5μg/mL respectively for 48 hours in standard humidified 
incubator. Total RNA was extracted by Geneaid® RNA Mini Kit (cultured cells) (Geneaid, 
Taiwan) according to the manufacture’s instructions. The mRNA levels of the MMPs were 
determined by RT-PCR. Primer sequences for MMP-1, 3, 9 were previous described[6]. The 
relative target mRNA expression level was normalized by β-actin (forward
5’-CCTCTATGCCAACACAGTGC-3’ reverse 5’-ATACTCCTGCTTGCTGATCC -3’) in the 
same sample. PCR products were electrophoretic displayed on a 2% agrose gel with ethidium 
bromide staining and captured in gel documentation system (Bio-Rad, Hercules, CA, USA).
Nuclear proteins were extracted from cultured cells as well. Protein concentrations were 
determined by using the Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). Sample proteins
were resolved by 10% sodium dodecylsulfate polyacrylamide gel electrophoresis and then 
electrophoretically transferred to nitrocellulose. The primary antibody of NFκB were added and 
incubated at 4˚C overnight. Then membranes were incubated with corresponding secondary 
antibodies for 1 hour. Protein bands were revealed by the ECL PLUS kit (GE. Healthcare 
Bio-Sciences, NJ, USA). The amount of NFκB protein was corrected by the signal of β-actin in 
the same sample. Quantification was achieved by quantifying the densities of the bands with the 
program of Quantity One.
The immunocytochemical studies for both cell lines were performed culturing in 24-well plate 
with glass-cover slides at a density of 105 cells/well for 24 hours. The application of curcumin 
(5μg/mL) was followed by 48 hours incubation. The cells were fixed and immunostained with 
the following antibodies: Cyclin D1, p21, CDK4 and NFκB. Staining was performed using 2% 
DAB substrate-chromogen solution. The intensity of DAB staining was examined under a 
standard light microscope using × 40 magnification. 
Statistical analysis was performed using SPSS 16.0 (SPAA Inc, Chicago, IL, USA) including the 
ANOVA test for pairwise comparisons. The continuous variables were analyzed by independent-
sample t test. All P values reported were two-sided with P < 0.05 considered significant. 
Experimental results were presented as the mean ± SD.
Results and Disscussion:
Effects of curcumin on breast cancer cell proliferation
Treatment of breast cancer cell BT-483 and MDA-MB-231 with curcumin exhibited inhibitory 
effect on cell growth (Figure 1). Curcumin with the dose as low as 1.25µg/ml was found to be 
effective on BT-483 and treatment with 5µg/ml for 48 h could result in a 60–70% inhibition. 
Curcumin with the dose as low as 2.5µg/ml was quite effective on MDA-MB-231 and treatment 
with 5µg/ml for 48 h resulted in a 50–60% inhibition. Thus we selected 5μg/mL concentration of 
curcumin as the optimal concentration for the subsequent experiments.
Fig. 1. (A) Chemical structure of curcumin. (B) Effects of curcumin on MDA-MB-231 and (C) 
BT-483 cell growth. Cultured cells were treated with various concentrations (0, 1, 1.5, 2.5, 5 and 
10 μg/ml) of curcumin for 24, and 48 hours as described in the text. The cell viability of cells 
was counted by WST-1 assay. The results were represented the mean ± S.D. of three independent 
experiments and the significant difference was established at *p < 0.05, **p < 0.001 compared 
with the control group for the indicated time. DMSO served as the solvent control.
Curcumin decreased Matrix metalloproteinases-1 expression in MDA-MB231 and BT-483
breast cancer cells
To determine whether curcumin can down regulate MMPs expression in breast cancer cells, 
BT-483 and MDA-MB-231 were treated with 2.5μg/mL, 5μg/mL curcumin for 48 hours, and
then the mRNA was isolated and probed with MMP-1, MMP-3 and MMP-9 cDNA respectively.
Curcumin at the concentration of 2.5μg/mL and 5μg/mL can down-regulated MMP-1 mRNA in 
BT-483 breast cancer cell and MDA-MB-231 breast cancer cell. In this study, 2.5μg/mL and 
5μg/mL curcumin have not showed inhibitory effect on MMP-3 or MMP-9 mRNA expression
Fig 2.Curcumin at 2.5 μg/mL and 5μg/mL can down-regulate MMP-1 mRNA in both cell lines, 
but no inhibitory effect on MMP-3 mRNA or MMP-9 mRNA expression.
Immunochemical detection of cyclin D1, CDK4 and p21 in MDA-MB231 and BT-483
breast cancer cells
MDA-MB-231 were incubated with curcumin at the 5μg/mL (Fig 3.1 B, D, F) and without 
curcumin ( Fig 3.1 A, C, E) for 48 hours. The intensity of DAB staining was examined under a 
light microscope on × 40 magnification. The intensity of the stain was assessed by their
thickness and darkness of the DAB precipitate.
BT-483 were incubated with curcumin at the concentration of 5μg/mL ( Fig 3.2 B, D, F) or 
without curcumin ( Fig 3.2 A, C, E) for 48 hours. The intensity of DAB staining was examined
under a light microscope with × 40 magnification. The intensity of the stain was assessed by
their thickness and darkness of the DAB precipitate.
Effect of curcumin on NFκB protein of MDA-MB231 and BT-483 breast cancer cells.
To investigate whether curcumin inhibit NF-κB in BT-483 and MDA-MB-231 human breast 
cancer, we perform immunostaining and western blot of NF-κB p65 protein. As shown in Fig. 5.
Treatment of BT-483 and MDA-MB-231 cell lines with curcumin at the concentration of 
5μg/mL for 12, 24, 48 hours respectively shown a reduced expression of nuclear NF-κB.
Fig. 4. Time course of curcumin treatment on NF-κB expression in MDA-MB-231 and BT-483
cells. (A)Cultured cells were treated with curcumin (5 μg/mL) for 48 h. The control group cells 
express strong nuclear and cytoplasmic p65 immunoreactivity (cells with strong nuclear staining, 
with or without minor cytoplasmic staining).Cells treated with curcumin shows decreased 
nuclear and cytoplasmic p65 immunopositivity compared to the controls.
(B) Cells were incubated with curcumin for three periods of time (0, 24 and 48 h). Nuclear 
extracts were prepared and assayed for NF-κB P65 by Western-blot as described in method 
section. All the samples were probed with beta-actin to normalize protein loading. The intensity 
of each western blotting band was analyzed by Quantity One software (Bio-Rad, Hercules, CA, 
USA). The results were represented the mean ± S.D. of three independent experiments and the 
significant difference was established at *p < 0.05, **p < 0.005 compared with the control group.
Treatment of breast cancer cell BT-483 and MDA-MB-231 with curcumin exhibited inhibitory 
effect on cell growth (Figure 1). In mammalian cells, the D cyclins with their catalytic partners, 
CDK4 and CDK6, function as the cells leave G0 and progress through G1 into S phase[7-9].
Three D-type cyclins, designated D1, D2, and D3, have been identified to date. D-cyclin 
isoforms have implicated a tissue and cell specificity and may play a different role during normal 
and tumor development. In majority of human breast cancers, deregulated overexpression of 
cyclin D1 is found[9]. The presence of specific CDK inhibitory proteins regulates the activities
of cyclins and CDKs. Whether curcumin modulate its anti-proliferative effects through the 
regulation of cyclin D1 was examined. Immunochemistry was carried out after treatment with
5μg/mL. The result showed that curcumin decreased cyclin D1 expression (Fig3.1B) in 
MDA-MB-231 while the decrease of cyclin D1 has not been observed in BT-483. Recently, the 
role of cyclin D3 in breast cancer progression has been suggested[10]. Cyclin D3 share a similar 
function as well as cyclin D1 in regulating the G1 check-point of the cell cycle. Though cyclin 
D3 share a similar function of cycline D1 inregulating the G1 check-pint of the cell cycle, the 
role of cyclin D3 in breast cancer progression had just been recently suggested.
Garcia-Morales[11] have identified that ER-positive MCF-7 breast cancer cells growth inhibition 
by rapamycin is due to a G1 arrest that specifically caused by cyclin D3 down-regulation but not 
cyclin D1. In our study, down-regulated cyclin D1 expression has not been found in ER-positive 
breast cancer BT-483, wherease a lower level of CDK4 expression has been found in BT-483 
treated with curcumin. It straightly indicates the decrease of CDK4 occurred in BT-483 could be 
interpreted as a consequence of the cyclin D3 loss but not the cyclin D1.
Proteins termed CDK inhibitory proteins including INK4 proteins and the Kip/Cip proteins can 
also bind to cyclin-Cdk complexes. Kip/Cip proteins, comprised of p27, p21, and p57, can 
inhibit each of the cyclin-CDK complexes being essential for G1 progression and S phase entry
[12]. p21cip1/waf1 is known to inhibit the kinase activity of the CDK4–Cyclin D1. Inhibition by 
p27 is another generally proposed mechanism to explain the inactivity of D-type cyclin-CDK4 
complexes [12]. p27 concentration allows the nuclear import and activation of cyclin D3-CDK4 
complexes [13]. We investigated curcumin’s regulatory effect on p21cip1/waf1 by 
immunochemistry. As results shown in Figure3F, we observed curcumin induced high level of
p21cip1/waf1 protein expression in MDA-MB-231 but failed to see such difference in case of
between ER-positive BT-483 cells no matter it treated with curcumin or not. The possibility that 
curcumin inhibits cyclin D3-CDK4 complex to bind p27 in breast caner related to ER status 
should be tested in the future study.
MMPs are a family of proteolytic enzymes that can degrade extracellular matrix (ECM) 
components including collagen, fibronectin, and laminin. Due to the significant role that MMPs 
play in cancer as well as additional human pathologies, giving interest has focused on identifying 
natural and synthetic compounds that can inhibit MMP activities. Curcumin has been reported 
that it can inhibit the activity of MMP2 in MDA-MB-231 cell line by western blot [14]. Our 
RT-PCR result showed that curcumin can inhibit the mRNA expression of MMP-1 in 
MDA-MB-231 and BT-483 while having no effect on the MMP-3, 9. 
Constantly activated NF-κB directly induce genes that promote cell proliferation including cyclin 
D1 and the cyclin-dependent kinase inhibitors p21[4]. The transcription factor NFκB has also 
been shown to be critically involved in the regulation of MMP-1, MMP-3[15]. Curcumin has 
been reported to have a synergistic effect against the growth of both ER-positive and 
ER-negative cells[14]. We proposed that curcumin may suppress NF-κB which in turn 
suppressing MMPs, cyclin D1. Under the normal conditions, NF-κB as an inactive heterotrimer 
present in the cytoplasm. Cytokines such as TNF-α and environmental hazards like ionizing 
radiation or toxins trigger the translocation of NF-κB from the cytoplasm to the nucleus. 
Activation of this transcription factor protects a variety of cell types from the damage that
induced by pro-apoptotic stimuli[16]. It is therefore, inhibition of NF-κB activity is not only 
desirable in the treatment of inflammation but also in cancer therapy. Curcumin decreased 
nuclear and cytoplasmic p65 immunopositivity of both BT-483 and MDA-MB-231 cells. 
Curcumin inhibited intranuclear expression of NF-κB p65 in MDA-MB-231 and BT-483 cells
were also confirmed by western blot. 
Breast cancer often progresses from the estrogen-dependent, nonmetastatic phenotype to the 
estrogen-independent, metastatic phenotypes. This progression is usually accompanied by altered 
function of the estrogen receptor or outgrowth of ER-negative cancer cells with generally high 
constitutive activity of NF-κB[17]. Although many estrogen receptor-positive breast cancers 
initially respond to antihormones drugs, responses are commonly incomplete when resistance 
ultimately emerging. Preclinical studies suggest that treatment strategies designed to prevent or 
interrupt activation of NF-κB in cell-line models of ER-positive breast cancers can restore their 
sensitivity to such standard endocrine agents as tamoxifen. On the other hand, activated ER can 
inhibit both NF-κB activation and the ability of NF-κB to regulate gene expression[18]. Further 
studies are necessary to investigagte how curcumin suppress the activation of NF-κB via
inhibition of osteoclastogenesis in ER-positive breast cancer cell. Conceivably, our results show 
that curcumin can treat both ER-negative breast cancer (with generally high constitutive activity 
of NF-κB) and perhaps hormone-resistant ER-positive breast cancer via inhibiting the activation 
of NF-κB.
In summary, our finding extrapolates the antitumor activity of curcumin in mediating the breast 
cancer cell proliferative rate and invasion by down-regulating the NF-κB B inducing genes. Our 
findings suggest curcumin could be a potentially therapeutic agent for both ER-positive and 
ER-negative breast cancer.
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